Journal of Physical Therapy Science
Online ISSN : 2187-5626
Print ISSN : 0915-5287
ISSN-L : 0915-5287
Case Study
Physical therapy for multiple myeloma patients with severely hindered daily living activities due to bone lesions: a report of two cases
Ryohei JinboTakaaki FujitaRyuichi KasaharaShinichiro MorishitaYuichi YamamotoKazumi JinboAya TakanoJunko KubotaShoko TakahashiYutaka ShigaHideo KimuraMiki FurukawaTatsuyuki Kai
著者情報
ジャーナル オープンアクセス

2021 年 33 巻 10 号 p. 795-800

詳細
抄録

[Purpose] Physical therapy for patients with multiple myeloma requires appropriate exercise intensity and risk management due to osteolytic lesions. However, the optimal strategy for setting exercise intensity remains unclear. We report cases in which physical therapy was performed using the Borg scale and the Common Terminology Criteria for Adverse Events v4.0 as indicators of improvement in the performance of activities of daily living without causing adverse events. [Participants and Methods] Two patients with multiple myeloma, whose performance status was 4, underwent resistance training of the upper and lower limbs and activities of daily living practice in stages according to their functional status. Each exercise was performed for 20 to 40 minutes twice a day for 6 days a week. The exercise intensity was set to 13 on the Borg scale as a guide, and the allowable bone pain was up to Grade 1 according to Common Terminology Criteria for Adverse Events v4.0. [Results] No adverse events occurred in either patient, and the performance status improved to 1 or 2. Subsequently, autologous peripheral hematopoietic stem cell transplantation was performed. [Conclusion] Physical therapy with exercise intensity set to 13 on the Borg scale and Grade 1 per Common Terminology Criteria for Adverse Events v4.0 may safely improve the performance of activities of daily living of patients with multiple myeloma.

著者関連情報
© 2021 by the Society of Physical Therapy Science. Published by IPEC Inc.

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
前の記事
feedback
Top